2nd Swiss Russian Health Forum
Basel September 10 and 11, 2012
Welcome in Basel!

The Swiss Russian Forum Foundation (SRF), created in 2006 as a non-profit organisation under Swiss Law, runs four platforms: Law, Finance, Science and Technology and, last but not least, Health.

In October 2011, the Swiss Russian Health Forum was launched in Moscow. This Conference on Healthcare was very successful as an initial event, but the really good news is, in fact, that several ideas of cross-country cooperation in various fields became concrete projects which in the meantime have been realised.

And now we are looking forward to the second edition of the Swiss Russian Health Forum in Basel, a truly ideal venue for an international gathering on healthcare: doctors, scientists, students, as well as representatives of the pharmaceutical and the medtech industries and politicians will get together at the University of Basel for two days of professional discussions and interdisciplinary networking...

Welcome!

Béatrice G. Lombard-Martin
Executive President, Founder, Swiss Russian Forum

Dear Participants of the Swiss-Russian Health Forum

This is already the second time when you gather to discuss the most burning issues of the public health in Switzerland and in Russia, new approaches and the best practices in treatment of various diseases that pose a threat to our nations.

I am glad that today my country, Switzerland, is hosting this event. Moreover, it is a real pleasure to realise that the idea of the Swiss Russian Health Forum once introduced in Moscow back in 2010 by the Swiss Embassy and the Swiss Russian Forum Foundation lives and is supported by the Swiss and Russian medical communities and business.

It is also very important that our political leaders who set up priorities for further development of our countries strongly back this event and cooperative endeavors between our countries in this field, as improving life quality of people is the top priority both in Switzerland and in Russia.

Our countries are well-known world-wide for their scientific achievements. And rallying our intellectual forces to combat diseases will definitely result in a better life quality of our peoples.

Therefore, I strongly encourage you to meet your colleagues, to share your experiences, to form partnerships, to expand your horizons – for we should not rest on our past and present accomplishments – on the contrary, they should serve as an incentive for our further development.

And I am sure that the Swiss Russian Health Forum that is taking place in Basel, the Swiss and World Life Sciences Hub, will be instrumental in this respect. Our countries can offer a lot to each other and we should use this opportunity. I wish you all the best in your work!

Pierre Helg
Ambassador of Switzerland to the Russian Federation
Introduction
The interdisciplinary aspect of the inaugural SRHF in Moscow last October turned out to be of central importance for its success: the Second Edition of the Health Forum in Basel will therefore again bring together doctors, scientists and representatives of the Pharmaceutical and Med-tech industries, as well as key political figures: innovative cooperation models are to be discovered, new target groups will be approached and different political requirements will be discussed.

The Three Major Issues of the 2nd Swiss Russian Health Forum
Following the advice of our Swiss and Russian partners and based on the experience of last year we will highlight only a limited number of medical disciplines at each SRHF:
- Regulatory Conditions
- Medicine and research
- New Technologies

The opening part of this year's SRHF will be devoted to Regulatory and Legal Requirements in Healthcare. Topics which are of paramount importance to cross-national cooperation shall be looked into in detail, such as authorisation, registration and licencing of pharmaceutical products, medical devices and generic drugs. The protection of intellectual property, standards, and specifications for production, trade, import and export round up this part.

Then on the second day the emphasis is put on innovative treatments in medical disciplines. This year Haematology/Oncology will be the topic in focus and New Technologies will concentrate on Advanced Laboratory Techniques in Blood Studies, Trends in Nanotechnology, Personalised Medicine as well as ICT in Healthcare.

Postgraduates
Particular emphasis will be put on furthering and supporting young doctors and scientists: Postgraduates are invited to contribute to the SRHF’s first poster exhibition and discuss their research with leading experts and professors in the field.

Scientific Publications
An important new feature of the 2nd SRHF will be the scientific publications, extending the information to an additional public: Speakers at scientific sessions can have their abstracts published in the scientific magazine "British Journal of Medicine and Medical Research", edited by ScienceDomain International (Delhi – London – Boston). The journal’s Editor-in-Chief is Professor Vladimir Kuznetsov.

Organiser
Swiss Russian Forum Foundation – a non-profit organisation according to Swiss law, domiciled in Zurich

Co-organiser
- Association of organizations and institutions of support and development of public health and medical industry, domiciled in Moscow
- IBS Expo Advertising Agency, domiciled in Moscow.

Cooperation
- Canton of Basel
- Russian Association of Organisations & Institutions of Support and Development of Public Health and Medical Industry (AZMP)
- N.I. Pirogov National Research Medical University, Moscow
- Almazov, Federal Heart, Blood and Endocrinology Centre, St. Petersburg
- Blokhin Centre, Moscow
- University Hospital Basel
- Swiss Biotech Association
- Universities of Basel, Berne, Zurich, Lausanne, Geneva
- Ministries of Health of Switzerland and the Russian Federation

Advisory Inputs
- Swiss Academy of Medical Sciences
- Russian Academy of Medical Sciences

Changing the practice of medicine
At Novartis, we want to discover, develop and provide high-quality healthcare solutions to address the evolving needs of patients and societies worldwide. We believe that our diverse healthcare portfolio, our dedication to innovation, and our responsible approach will enable us to fulfill our mission to care and to cure.
# 2nd Swiss Russian Health Forum

## Programme

### Day 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00</td>
<td>SENSELESS – A Forum with a difference</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>13.00</td>
<td>Opening Plenary</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>14.30</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>15.00</td>
<td>Regulations and Legal Environment</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>15.45</td>
<td>Intellectual Property and Market Entry</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>16.00</td>
<td>Personalised Medicine</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>18.30</td>
<td>Departure to Novartis Campus</td>
<td></td>
</tr>
</tbody>
</table>

### Day 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Reproductive Endocrinology</td>
<td>Auditorium 117</td>
</tr>
<tr>
<td>10.45</td>
<td>Haematology/Oncology</td>
<td>Auditorium 118</td>
</tr>
<tr>
<td>10.30</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>10.45</td>
<td>Haematology/Oncology</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>12.45</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12.45</td>
<td>Haematology/Oncology</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>13.45</td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>16.00</td>
<td>Laboratory Techniques in Blood Studies/Nanotechnology</td>
<td>Auditorium 033 (Aula)</td>
</tr>
<tr>
<td>17.30–18.00</td>
<td>Closing Plenary</td>
<td>Auditorium 033 (Aula)</td>
</tr>
</tbody>
</table>

** Ore affordable. But never cheap.**

We Swiss don’t just think about price, we also think about value. Fly with us and you’ll see what we mean: small prices, big values, efficient transit, and service that makes time fly. SWISS operates 5 direct daily flights from RU to CH.

*The best offers are always present at [SWISS.COM](http://www.swiss.com)*

---

**Founded in Geneva in 2008 by the Timchenko family, Fondation Neva aims at reinforcing ties between Russia and Switzerland. The foundation supports projects promoting excellence in the field of culture, science and sports.**

*www.neva-fondation.org*
Day 1: Healthcare: Regulatory Conditions/Environment for Innovation

Sunday, September 09

Welcome of Russian Guests in Basel
19.30 University Hospital Basel

Day 1

Monday, September 10

Cultural Welcome
12.00 SENSELESS – A Forum with a difference
Helping to reduce the SENSELESS number of lives lost through lack of diseases awareness.
Closing by
Igor V. Reshetov (MD), Professor, Corresponding Member of Russian Academy of Medical Sciences,
Head of Microsurgery department of Moscow Scientific Research Institute of Oncology, P.A. Herzen,
Moscow

Welcome Addresses and Keynote Speeches
13.00 Welcome by
Pierre Helg, Ambassador, Embassy of Switzerland to the Russian Federation in Moscow
Béatrice Lombard-Martin, Executive President of the SRHF
Carlo Conti, Minister of Health of the Canton Basel, Deputy Head of the Government of the Canton Basel,
Chairman of the Conference of Cantonal Health Ministers, President of the Board of Swissmedic

Keynote speeches by
Healthcare System – Challenges in the Socio-Economic Environment in Switzerland
Alain Berset, Swiss Federal Councillor, Head of the Federal Department of Home Affairs FDHA, Berne

Healthcare System - Challenges in the Socio-Economic Environment in the Russian Federation
Igor Kagramanyan, Deputy Minister of Health and Social Affairs, Moscow
Sergey Muraviev, Head Department of International Cooperation and Public Affairs
Ministry of Health, Moscow
Valeriy Chereshnev, Chairman of the Science Committee of the State Duma, Moscow

Regulations and Legal Environment
Monday, September 10

Registration and Harmonisation of Medical Products in Switzerland
Petra Doerr (MD), Board Member of Swissmedic, Berne

New opportunities and challenges of the Russian Pharma 2020 program: overview of clinical trial and pharmaceutical development environments
Vladimir Bogin, (MD), ABIM, CEO Cromos Pharma, LLC, Chairman of the Board Medistem Inc.
and Tross Laboratories, LLC, Moscow

Opportunity of Russian Health Technology Assessment System Development
Ramil Khabriev (MD), Professor, Member of Russian Academy of Medical Sciences,
a.i. Vice-Principal of the Russian State Medical University after N.I. Pirogov, Moscow

Clinical Research and Clinical Trials in Switzerland
Jürg Lustenberger (PhD), Dipl. Pharm. Med. SwAPP, Clinical Trials Centre, University of Zurich,
Zurich

Practical Experience of Pharmacoeconomics Models for Russian HTA Systems
RozaYagudina (MD), Professor, Head Department of Organisation of Medical Supply,
First Moscow Medical State University I.M. Sechenov, Moscow

Off label use in Switzerland
Jürg Nadig (MD), MAE, President Swiss Society of Medical Oncology, Bülach

Intellectual Property and Market Entry
Monday, September 10

Environment for Drug Development in Switzerland and the Russian Federation – Distinctions and Synergies
Stefan Kohler (PhD), Attorney-at-law, Head of Life Sciences Group, Vischer Ltd, Basel/Zurich

How to Protect, Develop and Bring onto the Market your Drug Innovation in the Russian Federation?
Vladimir G. Shipkov, Association of International Pharmaceutical Manufacturers (AIPM), Moscow (tbd)

How to Protect, Develop and Bring onto the Market your Drug Innovation in Switzerland?
Stefan Kohler (PhD), Attorney-at-law, Head of Life Sciences Group, Vischer Ltd, Basel/Zurich

Personalised Medicine and Impact of New Technologies
Monday, September 10

The Road to Personalised Precision Health Care
Ernst Hafen (PhD), Professor, former President of The Federal Institute of Technology Zurich,
Head Institute of Molecular Systems Biology, Federal Institute of Technology Zurich, Zurich

Personalized Medicine and the Personal Drug Response Profile
Urs A. Meyer (MD), Professor of Pharmacology, Biozentrum, University of Basel, Basel
DAY 2

2 Healthcare: Medicine and Research/Innovative Treatments

Haematology/Oncology  
**Tuesday, September 11**

**Chairs:**
- Christoph Renner (MD), Professor, Head Department of Internal Medicine Oncology, University Hospital Zurich, Zurich
- Jakob Passweg (MD), Professor, Head Department of Hematology University Hospital Basel, President Swiss Cancer League, Basel

Cell Based and Gene Therapies  
**Tuesday, September 11**

**Autologous Stemcell Programme**
- Christoph Renner (MD), Professor, Head Department of Internal Medicine Oncology, University Hospital Zurich

**Plateletrich Plasma and Collagen Preparation in Treating Patients with Nonhealing Chronic Wounds**
- Vladimir N. Obolensky (MD), City Clinical Hospital N°13, Russian National Research Medical University, Moscow

**Regenerative Medicine and Biotechnology**
- Vitaly Morozov (MD), Professor, Advanced Medical Technologies Centre (ICBFM), Novosibirsk

**The Future of Stem Cell Transplantation**
- Jakob Passweg (MD), Professor, Head Department of Hematology University Hospital Basel, President Swiss Cancer League, Basel

**Gene Therapy with Adoptive T-Cell Transfer**
- Ulf Petrasch, (MD), Professor, Senior Physician, Division of Immunology, University Hospital Zurich, Zurich

**Optimised gene constructs for expression of therapeutic genes in liver cells**
- Chavdar Pavlov, (MD), Professor and Deputy Director of the Clinic of Internal Diseases Propaedeutics, Gastroenterology and Hepatology, „Sechenov“ First Moscow Medical State University, Moscow
DAY 2

Healthcare: Medicine and Research/Innovative Treatments

2 Oncology – Translational Research

Tuesday, September 11

Chairs:
- David Zaridze (MD, DSc), Deputy Director, Russian N. N. Blokhin Cancer Research Centre, RAMS, Invited Professor of Epidemiology, Oxford University, Senior Scientist, International Prevention Research Institute, Lyon
- Christoph Rochlitz (MD), Professor, Head Oncology, University Hospital Basel, Basel

Molecular Epidemiology of cancer; prospects for translation
- David Zaridze (MD), Professor, Deputy Director, Russian N. N. Blokhin Cancer Research Centre, Head of Department of Epidemiology and Prevention, Moscow

Here we need talks on breast, colon, lung cancer etc.
- Christoph Rochlitz (MD), Professor, Head Oncology, University Hospital Basel, Basel

Evolution of therapeutic concepts in renal cell carcinoma
- Frank Stenner (MD), Senior Physician of Oncology Department, University Hospital Basel, Basel

Stereotactic radiotherapy and radiosurgery: Facts and visions
- Daniel Aebersold (MD), Professor, Director and Chairman, Department of Radiation Oncology, University of Bern, Inselspital, Bern

Molecular analyses of sensitivity to target therapy in patients with lung, colorectal cancer and GISTs
- Natalia Mazurenko (MD), Professor, Head of the Department of Oncogenomics, Russian N. N. Blokhin Cancer Research Centre, Moscow

Predictive biomarkers and targeted therapy in advanced non-small cell lung cancer
- Sacha Rothschild (MD), Senior Physician of Oncology Department, University Hospital Basel, Basel

Gynecologic cancer – a brief update and new treatment options
- Marcus Vetter (MD), Professor, Head Oncology, University Hospital Basel, Basel

From Systems Biology to Personalised Medicine: How to identify actionable drug targets and translate them into personalised treatments in clinic?
- Tatyana Nikolaykaya (MD), Head of Laboratory for Translational Research & Personalised Medicine, Department of Molecular Biology and Physics at MIPT, Dolgoprudnyj, Moscow Region

Tissue-specific transcription factor HNF4a: from experimental tool to prognostic marker
- Natalia Lazarevich (MD), Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow

Vascularisation of the surface covering epithelium in cancer patients: a new insight into a possible mechanism of cancer pathogenesis
- Apollon Karseladze (MD), Head Department of Pathology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Understanding and treating triple negative breast cancer
- Monia Frolova (MD), Scientific Fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Chemotherapy for pure prognosis non-seminoma germ-cell tumours
- Michail Fedyanin (MD), Scientific fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Disruption of stable cell-cell adhesion and acquisition of a motile phenotype in neo-plastically transformed epithelial cells: the role of the actin cytoskeleton and E-cadherin-based adherens junctions
- Natalia Glushankova (MD), Leading Scientific Fellow, Laboratory of Mechanisms of Carcinogenesis, Carcinogenesis Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow

From Systems Biology to Personalised Medicine: How to identify “actionable” drug targets and translate them into personalized treatments in clinic?
- Christoph Rochlitz (MD), Professor, Head Oncology, University Hospital Basel, Basel

Molecular analyses of sensitivity to target therapy in patients with lung, colorectal cancer and GISTs
- Natalia Mazurenko (MD), Professor, Head of the Department of Oncogenomics, Russian N. N. Blokhin Cancer Research Centre, Moscow

Predictive biomarkers and targeted therapy in advanced non-small cell lung cancer
- Sacha Rothschild (MD), Senior Physician of Oncology Department, University Hospital Basel, Basel

Gynecologic cancer – a brief update and new treatment options
- Marcus Vetter (MD), Professor, Head Oncology, University Hospital Basel, Basel

From Systems Biology to Personalised Medicine: How to identify actionable drug targets and translate them into personalised treatments in clinic?
- Tatyana Nikolaykaya (MD), Head of Laboratory for Translational Research & Personalised Medicine, Department of Molecular Biology and Physics at MIPT, Dolgoprudnyj, Moscow Region

Tissue-specific transcription factor HNF4a: from experimental tool to prognostic marker
- Natalia Lazarevich (MD), Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow

Vascularisation of the surface covering epithelium in cancer patients: a new insight into a possible mechanism of cancer pathogenesis
- Apollon Karseladze (MD), Head Department of Pathology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Understanding and treating triple negative breast cancer
- Monia Frolova (MD), Scientific Fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Chemotherapy for pure prognosis non-seminoma germ-cell tumours
- Michail Fedyanin (MD), Scientific fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Disruption of stable cell-cell adhesion and acquisition of a motile phenotype in neo-plastically transformed epithelial cells: the role of the actin cytoskeleton and E-cadherin-based adherens junctions
- Natalia Glushankova (MD), Leading Scientific Fellow, Laboratory of Mechanisms of Carcinogenesis, Carcinogenesis Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow

From Systems Biology to Personalised Medicine: How to identify “actionable” drug targets and translate them into personalized treatments in clinic?
- Christoph Rochlitz (MD), Professor, Head Oncology, University Hospital Basel, Basel

Molecular analyses of sensitivity to target therapy in patients with lung, colorectal cancer and GISTs
- Natalia Mazurenko (MD), Professor, Head of the Department of Oncogenomics, Russian N. N. Blokhin Cancer Research Centre, Moscow

Predictive biomarkers and targeted therapy in advanced non-small cell lung cancer
- Sacha Rothschild (MD), Senior Physician of Oncology Department, University Hospital Basel, Basel

Gynecologic cancer – a brief update and new treatment options
- Marcus Vetter (MD), Professor, Head Oncology, University Hospital Basel, Basel

From Systems Biology to Personalised Medicine: How to identify actionable drug targets and translate them into personalised treatments in clinic?
- Tatyana Nikolaykaya (MD), Head of Laboratory for Translational Research & Personalised Medicine, Department of Molecular Biology and Physics at MIPT, Dolgoprudnyj, Moscow Region

Tissue-specific transcription factor HNF4a: from experimental tool to prognostic marker
- Natalia Lazarevich (MD), Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow

Vascularisation of the surface covering epithelium in cancer patients: a new insight into a possible mechanism of cancer pathogenesis
- Apollon Karseladze (MD), Head Department of Pathology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Understanding and treating triple negative breast cancer
- Monia Frolova (MD), Scientific Fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Chemotherapy for pure prognosis non-seminoma germ-cell tumours
- Michail Fedyanin (MD), Scientific fellow, Department of Clinical Pharmacology, Russian N. N. Blokhin Cancer Research Centre, Moscow

Disruption of stable cell-cell adhesion and acquisition of a motile phenotype in neo-plastically transformed epithelial cells: the role of the actin cytoskeleton and E-cadherin-based adherens junctions
- Natalia Glushankova (MD), Leading Scientific Fellow, Laboratory of Mechanisms of Carcinogenesis, Carcinogenesis Institute of Carcinogenesis, Russian N. N. Blokhin Cancer Research Centre, Moscow
DAY 2 Healthcare: Medicine and Research/Innovative Treatments

Reproductive Endocrinology

Chair: Bruno Imthurn (MD), Professor, Head Division, Reproductive Endocrinology, University Hospital Zurich, Zurich

Legal and Regulatory Framework for Reproductive Medicine in Russia & Switzerland – Differences and Similarities
Bruno Imthurn (MD), Professor, Head Division Reproductive Endocrinology, University Hospital Zurich, Zurich

Experiences and Results of the Swiss IVF-Registry
Christian M. H. R. De Geyter (MD), Professor, University Hospital Basel, President Swiss IVF Registry “FIVNAT-CH”, Basel

Ophthalmology

Chairs: Bernhard Henrich (MD), Department of Ophthalmology, University of Basel, Basel

Atomic Force Microscopy: New insights into the material properties of the internal limiting membrane
Bernhard Henrich (MD), Department of Ophthalmology, University of Basel, Basel

Current Approaches to the Diagnosis and Treatment of the Major Reasons of Blindness: Glaucoma, Cataract, A(MD)/DME

(Speaker by Novartis)

High-frequency electric welding of biological tissues in vitreoretinal surgery
Nikolai Umanets, (MD), Head of Group on Development of New Technologies in Vitreoretinal Surgery, Odessa

The comparative evaluation of retina functions in the patients with open and closed eye globe traumas
Maria Chekalova M.V., Moscow Helmholtz Research Institute of Eye Diseases, Moscow


Advanced Laboratory Techniques in Blood Studies/ Trends in Nanotechnology

Chairs: Dmitri Kuznetsov (MD), Professor, N.I. Russian National Research Medical University, Moscow
Nicolas Vuilleumier (MD, PhD), Head Clinical Chemistry and Toxicology at the Medical Laboratories, University Hospital Geneva
Joerg Huwyler (PhD), Professor, Head of the Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel

Industrial Technologies & Experimental Nanobiotechnologies in Blood Studies
Vladimir P. Chekhonin (MD), Professor, Chairman Nanobiotechnology, N. I. Pirogov National Research Medical University, Moscow

Radiospectroscopic Studies of Blood Plasma Proteins and Cells: Free Radical and Antioxidant Aspects
Anatoly N. Osipov (MD), Professor, Head of Department Medical Biophysics, N. I. Pirogov Russian National Research Medical University, Moscow

Luminiscent Assays in Blood Tests: Probes and Kinetic Measurements
Yuri A. Vladimirov (MD), Professor, Head of Department Biophysics, Faculty of Fundamental Medicine, M. V. Lomonosov Moscow State University, Moscow

Anti-apolipoprotein A-1 IgG as an emergent prognostic marker of cardiovascular risk: a translational approach
Nicolas Vuilleumier (MD, PhD), Head Clinical Chemistry and Toxicology at the Medical Laboratories, University Hospital Geneva

Molecular Aberrations in Histiocytic Disorders
Alexey A. Maschan (MD), Professor, Deputy Director, Russian Federal Research Centre for Pediatric Haematology, Oncology & Immunology, Moscow

Combi-drug formulations for phenotyping cocktails
Maxim Puchkov (PhD), Division of Pharmaceutical Technology, University of Basel
Joerg Huwyler (PhD), Professor, Head of the Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel

Nanocarriers: Are they really promising in Pharmacology?
Dmitry A. Kuznetsov (MD), Professor, N.I. Pirogov Russian National Research Medical University, Moscow

Nanocontainers: Are Hematopoietic Progenitor and Neuronal Stem Cells in Cancer Therapy
Vladimir P. Chekhonin (MD), Professor, N. I. Pirogov Russian National Research Medical University, Moscow

Nanotech approaches – Hematopoietic Progenitor and Neuronal Stem Cells in Cancer Therapy
Vladimir P. Chekhonin (MD), Professor, N. I. Pirogov Russian National Research Medical University, Moscow
DAY 2

3 Healthcare: New Technologies/Research Programmes & Foresight

Technical Advances over the next Decade
Tuesday, September 11

Moderation: Ernst Hafen (PhD), Professor, former President of The Federal Institute of Technology Zurich, Head Institute of Molecular Systems Biology, Federal Institute of Technology Zurich, Zurich

Roundtable: Advances in Health Care will not only grow out of the existing medical system but come from neighbouring fields such as Mobile Computing, Computer Science, Robotics, Social Media and Ethics.

5 Industry, Investors and Inventors

From Research to Products
Tuesday, September 11

Russian Federation:
- Impact of the huge domestic market on innovation and the Swiss/Russian healthcare industry
- The Russian role in the international healthcare market with a focus on...
- Technology Development: Aseptic Isolators in the Healthcare Industry

Switzerland:
- Highly specialized industry delivering high quality products in a small home market with high pressure for internationalisation and export. (Technology driven Innovation)
- The Swiss role in the international healthcare market

New laser microscope for biomedical live cell research and drug discovery
- Pavel A. Osipov, General Director “Laboratory AMFORA”, Moscow

GMP and Safety Compliant Production of Sterile, Sterile Toxic or Toxic Pharmaceutical Products in Hospitals and the Industry
- Paul Ruffieux (MD), Vice President SKAN AG, Allschwil

Integration of Various Medical Information Systems
- Matthias Stromberger, Strategy Management and Owner of Dorner Health IT Solutions

Closing Plenary

Results
Tuesday, September 11

- Results with short presentations
- Further procedure 2012/2013 and next steps
- Invitation 2013